Back to Authors

Miller, Bruce L.

https://orcid.org/0000-0002-2152-4220

A5046120768 | I180670191

Mayo Clinic

University of California, San Francisco

Citations 127

An algorithm for genetic testing of frontotemporal lobar degeneration

Neurology | January 31, 2011 | Volume: 76 | Issue: 5 | Pages: 475-483

10.1212/wnl.0b013e31820a0d13 | PMID 21282594

TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers

Neurology | December 22, 2010 | Volume: 76 | Issue: 5 | Pages: 467-474

10.1212/wnl.0b013e31820a0e3b | PMID 21178100

Off-Label Medication Use in Frontotemporal Dementia

American Journal of Alzheimer's Disease & Other Dementias® | February 1, 2010 | Volume: 25 | Issue: 2 | Pages: 128-133

10.1177/1533317509356692 | PMID 20124256

Objective: There are no Food and Drug Administration (FDA)-approved medications indicated for the treatment of frontotemporal dementia (FTD). We sought to determine the most commonly used drugs used to treat behavioral variant FTD (bvFTD) in specialized dementia clinics. Methods: Medication and demographic data from the Alzheimer’s Disease Research Centers of California (ARCC) and a multicenter FTD natural history study (NHS) data set were compared in bvFTD and Alzheimer’s disease (AD), and effects of demographic variables were assessed using logistic regression. Results: Overall, the percentage of patients taking one or more FDA-approved AD or psychiatric medications was similar in bvFTD and AD; however, after controlling for demographic variables, acetylcholinesterase inhibitor (AChI) use was less common in bvFTD, whereas memantine use remained similar in the 2 groups. Conclusions: Despite lack of evidence for efficacy, the use of AChIs and memantine is common in bvFTD. Clinical trials should be pursued to determine the optimal therapeutic interventions for bvFTD.
Characterization of DCTN1 genetic variability in neurodegeneration

Neurology | June 8, 2009 | Volume: 72 | Issue: 23 | Pages: 2024-2028

10.1212/wnl.0b013e3181a92c4c | PMID 19506225

Brain and ventricular volumetric changes in frontotemporal lobar degeneration over 1 year

Neurology | May 26, 2009 | Volume: 72 | Issue: 21 | Pages: 1843-1849

10.1212/wnl.0b013e3181a71236 | PMID 19470967

New Genes, New Dilemmas: FTLD Genetics and Its Implications for Families

American Journal of Alzheimer's Disease & Other Dementias® | December 31, 2007 | Volume: 22 | Issue: 6 | Pages: 507-515

10.1177/1533317507306662 | PMID 18166610

After Alzheimer's disease, frontotemporal lobar degeneration (FTLD) is the second leading cause of dementia in persons less than 65 years of age. Up to 40% of FTLD cases have a positive family history. Research on these families has led to the discovery of four disease-causing genes: microtubule-associated protein tau ( MAPT), progranulin ( PGRN), valosin-containing protein ( VCP), and charged multivesicular body protein 2B ( CHMP2B). MAPT and PGRN are responsible for the largest number of familial cases. Each of these genes differs by disease mechanism. Moreover mutations in both genes are associated with significant interfamilial and intrafamilial phenotypic variation. Genetic counseling needs to address the differences between the PGRN and MAPT mutations as well as the variation in clinical symptoms. The aims of this article are to describe the genetics of the FTLD spectrum and aid in the genetic counseling of individuals who may carry genetic mutations.
A 34-year-old man with progressive behavioral and language disturbance

Neurology | January 3, 2007 | Volume: 68 | Issue: 1 | Pages: 68-74

10.1212/01.wnl.0000251313.89403.b3 | PMID 17200497